Analysts have adjusted their average 12-month price target for Abbott Laboratories (ABT) stock to $115.5, a slight decrease from $116.32. This new target implies a potential upside of approximately 29% from its June 11 closing price. The consensus rating among 29 analysts remains a "Buy," with 23 recommending Buy and 6 recommending Hold.

Medtronic's average 12-month stock price target has been adjusted down to $96.72 from $97.32, according to 25 analysts. This new target suggests a potential upside of approximately 20% from the June 11 closing price. The stock maintains a "Buy" consensus rating from 33 analysts.

Analysts have raised the average 12-month price target for TD SYNNEX Corporation (SNX) stock from $260.55 to $265.09, with individual forecasts ranging from $200 to $320. Based on the June 11 closing price, this new target suggests a potential 4% downside. Despite this, the consensus rating from 13 analysts remains a "Buy," with 10 recommending Buys and 3 recommending Holds.

Park Ha Biological Technology Co. (BYAH) shares surged nearly 170% in pre-market trading after announcing a partnership with Star Plus Action, a wholly-owned subsidiary of Star Plus Legend Group. This collaboration aims to create an integrated skincare and health ecosystem by combining expertise in skincare, healthcare, celebrity IP, and AI, including the launch of an AI Nutritionist and plans for AI-powered store managers and virtual skincare specialists. Despite an 87% year-to-date decline for BYAH stock, retail sentiment on Stocktwits is currently "extremely bullish."

Jeppesen ForeFlight, now divested from Boeing and under private equity ownership by Thoma Bravo, is focusing its future strategy on building trust in AI for aviation. Despite initial concerns stemming from layoffs and price increases post-acquisition, CEO Brad Surak emphasizes a cautious approach to AI integration, prioritizing reliability over speed to market. This strategy aims to solidify the company's role as a trusted steward of digital infrastructure in aviation, where its products are used by over 75% of pilots.

Cosmos Health reported over $1.5 million in combined annualized sales for its C-Scrub and C-Sept antiseptic brands in the UK and Greece, with gross margins exceeding 70%. The company plans to expand these brands across the EU and into the animal healthcare market, targeting $7.4 million in revenue and $5.3 million in gross profit by 2028. This expansion aims to leverage strong demand and competitive advantages in the antiseptics market.

Philip Morris (PM) maintains its Buy rating due to its leadership in smoke-free products, profitable growth, and secure dividend prospects. Smoke-free revenues, led by IQOS/ZYN/VEEV, now account for 43% of sales and support management’s 3-year adjusted EPS growth target of +10%. While the stock has an expensive P/E of 21.26x, it offers a decent dividend yield of 3.21%, making it a potential Buy on moderate corrections.

Nucor Corp stock has reached an all-time high of $264.40, reflecting an impressive 1-year total return of 123.6% for the $59.4 billion steel manufacturer. Despite an InvestingPro analysis suggesting it's overvalued, the company maintains a "GOOD" financial health score and recently reported robust Q1 2026 earnings, surpassing expectations, and declared its 213th consecutive quarterly dividend.

Piper Sandler has reduced its price target for Pepsico (NASDAQ:PEP) stock to $178 from $181, maintaining an Overweight rating, citing mounting input cost pressures and slower distribution momentum in salty snacks. Despite these headwinds, PepsiCo boasts a 54.4% gross profit margin and has a 53-year dividend increase streak, indicating financial resilience. The firm lowered its 2027 EPS estimate for PepsiCo but kept its 2026 estimate unchanged, with other recent news including a dividend increase and new analyst coverage.

Nucor Corp stock has reached an all-time high of $264.40, nearing its 52-week high of $264.67, driven by strong market performance and investor confidence. Despite analytical suggestions of overvaluation, the steel manufacturer maintains a "GOOD" financial health score, boasting a 1-year total return of 123.6%. The company also reported robust first-quarter 2026 earnings, exceeding expectations, and declared its 213th consecutive quarterly cash dividend.